A prospective, randomized, double‐blind trial evaluating the efficacy of ursodeoxycholic acid in prevention of liver transplant rejection

Jaquelyn F. Fleckenstein, Melinda Paredes, Paul J. Thuluvath – 30 December 2003 – Acute cellular rejection (ACR) after orthotopic liver transplantation occurs in 50% to 80% of patients despite the recent advances in immunosuppressive therapy. Adjuvant use of ursodeoxycholic acid (UDCA) is theoretically attractive, but studies have shown conflicting results. In this randomized, controlled study, we evaluated the efficacy of UDCA in reduction of the incidence of ACR.

Efficacy of neoral in the immediate postoperative period in children post–liver transplantation

I.D.M. van Mourik, H. Vilca Melendez, M. Thomson, G. Mieli‐Vergani, N. Heaton, D.A. Kelly – 30 December 2003 – Cyclosporine (Sandimmune) is an effective immunosuppressive drug but may be poorly absorbed in the early postoperative period after liver transplantation, exposing the recipient to an increased risk for rejection. Neoral is a new oral formulation of cyclosporine that uses a mixture of surfactant, lipophilic, and hydrophilic solvents to permit microemulsification that leads to potentially better absorption.

Trendelenburg positioning and continuous lateral rotation improve oxygenation in hepatopulmonary syndrome after liver transplantation

Christine Meyers, Lewis Low, Larry Kaufman, George Druger, Linda L. Wong, – 30 December 2003 – Hepatopulmonary syndrome (HPS) is characterized by hypoxia, orthodeoxia, and platypnea, associated with severe chronic liver disease. Liver transplantation is generally viewed as the only curative treatment for this syndrome, but it may be complicated by prolonged hypoxia after the procedure. We report on a 58‐year‐old female patient with alcoholic cirrhosis and HPS who underwent liver transplantation.

Nonspecificity of monoclonal antibody tordji‐22 for the detection of hepatitis C virus in liver transplant recipients with cholestatic hepatitis

Alison L. Doughty, Dorothy M. Painter, Geoffrey W. McCaughan – 30 December 2003 – Detection of hepatitis C virus (HCV) antigens in liver tissue provides important diagnostic and pathological information. Limited studies have been performed on tissue taken after liver transplantation for HCV. In this study, serial post–liver transplantation biopsy tissue from patients with recurrent HCV was tested, with particular interest in patients showing severe cholestatic hepatitis. HCV‐related antigens were detected using the commercial monoclonal antibody, Tordji‐22.

Pulmonary vascular morphological changes in cirrhotic patients undergoing liver transplantation

Laura W. Lamps, Kelly Carson, Anne L. Bradley, C. Wright Pinson, Joyce E. Johnson, Alice C. Coogan, Ellen B. Hunter, Pierre A. Clavien, Mary Kay Washington – 30 December 2003 – Cirrhosis and portal hypertension may be associated with pulmonary hypertension and pulmonary dysfunction. However, morphological pulmonary vascular lesions in patients with cirrhosis have not been well characterized morphometrically.

Changes in tissue oxygenation of the porcine liver measured by near‐infrared spectroscopy

Abd El El‐Desoky, Alexander Seifalian, Mark Cope, David Delpy, Brian Davidson – 30 December 2003 – Near‐infrared spectroscopy (NIRS) is a novel method for the measurement of tissue oxygenation and may have a role in monitoring liver oxygenation and viability. The aim of this study is to validate the application of NIRS for monitoring hepatic tissue oxygenation. Large Landrace pigs (n = 12) underwent laparotomy and liver exposure. Total hepatic blood flow (THBF) was measured by the Transonic Medical Flowmeter system.

Activation of nuclear factor‐κB during orthotopic liver transplantation in rats is protective and does not require kupffer cells

Cynthia A. Bradham, Peter Schemmer, Robert F. Stachlewitz, Ronald G. Thurman, David A. Brenner – 30 December 2003 – Reperfusion after liver transplantation results in the induction of tumor necrosis factor‐α (TNFα) as well as activation of the stress‐associated signaling proteins, c‐JunN‐terminal kinase (JNK), activating protein‐1 (AP‐1), and nuclear factor‐κB (NF‐κB).

Subscribe to